FMS Fresenius Medical Care AG Loading...

From DVA earnings calls
Loading chart...
Top Calls
Feed
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
0 selected
All Content✓
Source feeds
Buzzberg Top 50 ✓
All market capsNo capitalization filter✓
200 B and aboveMega✓
10 B to 200 BLarge✓
2 B to 10 BMid✓
0 to 2 BSmall✓
Custom
Enter market cap range in B USD
All directions✓
▲ Long✓
▼ Short✓
⛔ Avoid✓
✂ Close✓
◦ Others✓
Any score✓
LOW+✓
MED+✓
HIGH✓
21:00
Aug 04 ◎
Joel Ackerman CFO, DaVita Inc. DVA Q2 FY26 call
DaVita's treatment volume growth is being driven almost entirely by reduced mortality, not new patient starts, and it is outperforming the industry's negative same-store growth. — This confirms DaVita is gaining market share through superior clinical outcomes, a trend that could pressure competitors who cannot replicate the mortality improvements.
FMS
HIGH
21:00
May 05 ◎
Javier Rodriguez CEO, DaVita Inc. DVA Q1 FY26 call
DaVita expects to gain dialysis patients from Fresenius clinic closures, with half arriving in Q1 and most of the rest in Q2, contributing positively to 2026 volume growth. — Fresenius's network rationalization is ceding market share to DaVita, a direct transfer of volume and revenue.
FMS
HIGH

About FMS Analyst Coverage

Buzzberg tracks FMS (Fresenius Medical Care AG) across 1 sources. 0 bullish vs 0 bearish calls from 2 analysts. Sentiment: evenly split. 2 total trade ideas tracked. Latest voices: Joel Ackerman, Javier Rodriguez.